CDMO Cirrus Pharmaceuticals, a subsidiary of Kemwell, has announced the availability of cGMP inhaler manufacturing services for early phase clinical trials materials at its new facility in Raleigh-Durham, NC. Cirrus announced in October 2014 that it was investing in a new manufacturing suite for a variety of dosage forms, including OINDPs.
Cirrus VP of R&D Andrew Hamer commented, “We are very excited about this new service offering to customers. Cirrus will be one of the few CDMOs with development and manufacturing capabilities for some of the niche dosage forms we have to offer. Specifically, we will be able to perform manufacturing for metered dose inhalers (MDI) on our Pamasol pressure filling line. The typical batch size offering is up to 25L and Cirrus will be able to perform one and two-step filling as well as cold filling for suspension and solution MDIs. Other than MDIs in the inhaled dosage forms, we will offer our clients dry powder filling in capsules for dry powder inhalers (DPI), and manufacture of nasal solutions, suspensions, and powders.
Kemwell VP of Corporate Development Karan Bagaria said, “This new addition helps drive our goal to keep our customers competitive. We will now offer customers a seamless service from pre-formulation to clinical trial manufacturing in the US, and for oral solids and injectable products we can continue to offer commercial manufacturing from our plants in Sweden and India.”
Read the Cirrus press release.
